C‐terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease

Abstract

This study strengthens the potential of neurogranin as an AD CSF biomarker, which now needs validation in larger studies. As tools, straightforward immunoassays can be used, as demonstrated by the described ELISA.